The startup operates a drug discovery platform that utilizes artificial intelligence for new drug development, alongside molecular biology experiments and clinical trials. This approach accelerates the creation of effective therapies, addressing the urgent need for faster recovery options for patients.
Funding
Funding not disclosed
Founders
Product
Problem
The development of new drugs is a lengthy and expensive process, often taking many years and requiring significant investment. Traditional drug discovery methods can be inefficient, leading to delays in bringing effective therapies to patients in need.
Solution
Surginex is a drug discovery company that leverages artificial intelligence (AI) and next-generation lipid nanoparticles (LNPs) to accelerate the development of targeted therapeutics. The company's AI Odysseus Platform analyzes vast datasets to identify promising drug candidates and optimize treatment strategies. Surginex's LNP technology enables precise delivery of drugs, genes, and gene-editing tools to specific organs and cells, maximizing efficacy while minimizing side effects. In addition to its platform, Surginex offers customized exosome and molecular biology services.
Target Audience
Surginex serves pharmaceutical companies, research institutions, and researchers seeking to accelerate drug discovery and development, improve targeted drug delivery, and conduct preclinical studies.
Features
- AI-driven drug discovery platform (Odysseus) for identifying and developing novel therapeutic candidates.
- Next-generation lipid nanoparticle (LNP) technology for targeted drug delivery.
- Capability to deliver drugs, genes, and gene-editing tools with organ and cell specificity.
- Customized exosome services for targeted drug delivery research.
- Molecular biology services, including RNA and protein expression analysis.
- Histopathological services, including tissue slide preparation, staining, and image analysis.
- Gene experiment services, including customized CRISPR/Cas9 experiment design and RNA synthesis.
- Animal experiment services for preclinical drug evaluation.
- Physical/chemical analysis services for characterizing nanoparticles and samples.